Meeting of the National Vaccine Program Office on Vaccine Financing, 16684-16685 [E8-6433]
Download as PDF
<![CDATA[
16684
Federal Register / Vol. 73, No. 61 / Friday, March 28, 2008 / Notices
In compliance with the requirement
of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Office of the Secretary (OS), Department
of Health and Human Services, is
publishing the following summary of a
proposed collection for public
comment. Interested persons are invited
to send comments regarding this burden
estimate or any other aspect of this
collection of information, including any
of the following subjects: (1) The
necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions;
(2) the accuracy of the estimated
burden; (3) ways to enhance the quality,
utility, and clarity of the information to
be collected; and (4) the use of
automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
To obtain copies of the supporting
statement and any related forms for the
proposed paperwork collections
referenced above, e-mail your request,
including your address, phone number,
OMB number, and OS document
identifier, to
Sherette.funncoleman@hhs.gov, or call
the Reports Clearance Office on (202)
690–5683. Written comments and
recommendations for the proposed
information collections must be
received within 30 days of this notice
directly to the OS OMB Desk Officer.
All comments must be faxed to OMB at
202–395–6974.
Proposed Project: Evaluation of the
Parents Speak-Up National Campaign:
Youth Survey OMB No. 0990–New—
Office of Adolescent Pregnancy
Program.
Abstract: The Evaluation of the
Parents Speak-Up National Campaign
(PSUNC): Youth Survey is designed to
evaluate the Parents Speak-Up National
Campaign, a campaign designed to
encourage parents to talk with their
children about sexual activity. The
campaign includes paid and public
service announcement (PSA)-type spots,
as well as a Web site, 4parents.gov. As
the campaign aims to increase parentchild communication about sex, the
purpose of this information collection is
to measure youth self-reported
communication with parents, their
related attitudes and beliefs about sex,
and determine whether their parents’
exposure to PSUNC affects the youth
reports of communication. Parents of
the youth in this study are participating
in an OMB-approved, randomized
controlled study of the behavioral
effects of PSUNC message exposure.
This collection is follow-up of youth
aged 13–15 whose parents participated
in the parent efficacy study for the
campaign. We are requesting a 2 year
clearance.
ESTIMATED ANNUALIZED BURDEN TABLE
Number of
respondents
Forms
Type of respondent
Youth Survey ............................................
760
1
13–15 year old youth ...............................
Terry Nicolosi,
Office of the Secretary, Paperwork Reduction
Act Reports Clearance Officer.
[FR Doc. E8–6398 Filed 3–27–08; 8:45 am]
BILLING CODE 4150–30–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Vaccine
Program Office on Vaccine Financing
Department of Health and
Human Services, Office of the Secretary.
AGENCY:
ACTION:
Notice.
SUMMARY: The Department of Health and
Human Services (DHHS) is hereby
giving notice that the National Vaccine
Program Office (NVPO) will convene a
meeting of the Vaccine Finance Working
Group and is inviting input from
stakeholders on this issue. The meeting
will be open to the public.
The meeting will be held on
Tuesday, April 29, 2008 and
Wednesday, April 30, 2008. The
meeting will be held from 9 a.m. to 5
p.m. on both days.
DATES:
sroberts on PROD1PC70 with NOTICES
Number of
responses
per
respondent
Hilton Washington DC/
Rockville Hotel and Executive Meeting
ADDRESSES:
VerDate Aug<31>2005
17:57 Mar 27, 2008
Jkt 214001
Center; 1750 Rockville Pike, Rockville,
MD 20852–1699.
FOR FURTHER INFORMATION CONTACT:
Angela Shen, National Vaccine Program
Office, Department of Health and
Human Services, Room 443-H, Hubert
H. Humphrey Building, 200
Independence Avenue, SW.,
Washington, DC 20201; (202) 260–1587,
or e-mail angela.shen@hhs.gov.
SUPPLEMENTARY INFORMATION: NVPO has
responsibility for coordinating and
ensuring collaboration among the many
Federal agencies involved in vaccine
and immunization activities. The NVPO
provides leadership and coordination
among Federal agencies, as they work
together to carry out the goals of the
National Vaccine Plan. The National
Vaccine Plan provides a framework,
including goals, objectives, and
strategies, for pursuing the prevention of
infectious diseases through
immunizations. NVPO periodically
convenes working groups to address
specific issues and topics that impact
vaccine and immunization.
The Vaccine Finance Working Group
was established to address issues related
to vaccine financing in the United
States. The Working Group has
developed a draft white paper with a
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Average
burden
hours per
response
(in hours)
20/60
Total
burden
hours
253
number of policy options to be
considered for presentation to the
National Vaccine Advisory Committee
(NVAC) for discussion. NVPO has
charged the Vaccine Finance Working
Group to obtain input from stakeholders
whose viewpoints and interests can
help shape an understanding of the
issues that are relevant to the challenges
in creating optimal approaches to
vaccine financing in both the public and
private sectors.
The two-day meeting is scheduled to
be held to provide an opportunity for
vaccine financing stakeholders to
discuss and make comments on the
draft white paper and to solicit input, in
particular, regarding the conclusions
and options made by the working group
that are contained in the draft
document. A wide range of stakeholders
representing health care providers,
employers, payers, health insurers,
vaccine manufacturers and distributors,
consumers, and other interested parties
within the public health community are
invited to attend the meeting. Members
of the public will have the opportunity
to provide comments at the meeting.
Public comment will be limited to five
minutes per speaker. Any members of
the public who wish to have printed
material distributed to meeting
E:\FR\FM\28MRN1.SGM
28MRN1
Federal Register / Vol. 73, No. 61 / Friday, March 28, 2008 / Notices
participants should submit materials to
the NVPO staff person designated as the
contact for additional information. All
materials should be submitted to the
designated point of contact no later than
close of business April 21, 2008. Preregistration is required for public
comment. Any individual who wishes
to participate in the public comment
session should e-mail
angela.shen@hhs.gov or call 202–690–
5566.
There is limited space available for
the public to attend this meeting.
However, it is desired that the public
participate in the discussions, as well.
Registration is required to attend the
meeting; registration information can be
found at: https://
nvpo.constellagroup.com. Registration
for the meeting will be accepted until
April 5, 2008. Registration after that
date will be on the basis of space
availability. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the designated contact person.
Dated: March 24, 2008.
Bruce Gellin,
Director, National Vaccine Program Office.
[FR Doc. E8–6433 Filed 3–27–08; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[ATSDR–241]
Public Comments and Revised Final
Criteria for Removing Chemicals From
Future Editions of CDC’s National
Report on Human Exposure to
Environmental Chemicals
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
SUMMARY: On Tuesday, May 16, 2006,
CDC published draft criteria for
removing chemicals from future releases
of CDC’s National Report on Human
Exposure to Environmental Chemicals
(the ‘‘Report’’) (See FR, Vol. 71, No. 94,
p. 28346–7). This and previous notices
related to the ‘‘Report’’ are at https://
www.cdc.gov/exposurereport/
chemical_nominations.htm. The
proposed criteria provided that a
chemical may be removed from the
‘‘Report’’ if (1) a new replacement
chemical (i.e., a metabolite) is more
representative of exposure than is the
chemical currently measured; or (2)
after three survey periods (or not less
sroberts on PROD1PC70 with NOTICES
AGENCY:
VerDate Aug<31>2005
17:57 Mar 27, 2008
Jkt 214001
than 6 years), detection rates for all
chemicals within a methodological and
chemically related group are less than 5
percent for all population subgroups
(i.e., two sexes, three race/ethnicity
groups, and three age groups); or (3)
after three survey periods (or not less
than 6 years), levels of chemicals within
a methodological and chemically related
group are unchanged or declining in all
the specific subgroups as documented
in the ‘‘Report.’’
Using these criteria, CDC would have
continued to measure the chemical and
not remove it from the ‘‘Report’’ if it met
either of two proposed exceptions to
these criteria: (a) It is a chemical for
which there is an established
biomonitoring threshold (e.g., CDC’s
level of concern for blood lead levels in
children) or any chemical for which
there is widespread public health
concern (e.g., mercury) or (b) three
survey periods (or not less than 6 years)
have passed, constituting the minimum
time before a chemical could be
removed; a longer period may be
necessary to account for the half-life of
a particular chemical or to account for
a recent change (e.g., the removal of a
chemical from commerce) that would
necessitate monitoring of the
population. In that notice, CDC pointed
out that the criteria for removing a
chemical from the ‘‘Report’’ are not
corollaries of the criteria for adding
chemicals to the ‘‘Report.’’
Summary of Public Comments
CDC received 31 public comments on
the criteria cited above and describes
below the comments received and
CDC’s responses to those comments.
Comments are grouped in the following
categories: Removal process, criterion 1,
criterion 2, criterion 3, and exceptions
‘‘a’’ and ‘‘b.’’
General Informational Comments
Related to Process and Procedure
CDC received several public
comments about how the process of
removing chemicals from the ‘‘Report’’
would be implemented. These generally
pertained to (1) concurrence on the
scientific basis for exposure assessment;
(2) analytical cost considerations as
secondary; (3) description of the policy
basis for the process; (4) consideration
of and suggestions for alternative
approaches to limited sample volumes;
and (5) affirmation of decision
procedures, transparency, and public
notification.
CDC responses to general
informational comments:
Understanding exposures through
biomonitoring can help scientists focus
research on those chemicals found in
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
16685
people’s bodies and target the
appropriate levels of exposure. The
‘‘Report’’ provides unique exposure
assessment information and not
assessment of health risk. However, the
biomonitoring data in the ‘‘Report’’ can
facilitate and complement the riskassessment process. For some
chemicals, such as lead and mercury,
risks have become better characterized
when biomonitoring levels have become
the benchmark to which the risks are
tied. CDC considers the public health
utility and quality of biomonitoring
information to be the primary
consideration, with cost of analysis as
an important, but secondary,
consideration (See Federal Register Vol.
67, No. 34 March 20, 2002, pages
12996–7).
The policy basis for the development
of criteria for removing chemicals from
the ‘‘Report’’ was developed in
consideration of sound science and
resource utilization. With guidance from
a Work Group that was convened at the
direction of the Board of Scientific
Counselors of the National Center for
Environmental Health and the Agency
for Toxic Substances and Disease
Registry (NCEH/ATSDR), the proposed
criteria were established, and comments
from the public were solicited through
the Federal Register notice published in
May 2006 (Vol. 71, No. 94, p. 28346–7).
As currently described, only one of
the three criteria needs to apply to delist
a chemical. That is, the three criteria
apply independently—no combinations
of criteria are necessary to qualify a
chemical for removal from the ‘‘Report.’’
When chemicals published in the
‘‘Report’’ meet a criterion for removal,
they will be deleted from future reports.
The Division of Laboratory Sciences
(DLS) at NCEH will make these
decisions using the finalized criteria
only and will post the names of the
removed chemicals on its Web site:
https://www.cdc.gov/exposurereport.
Two commenters provided helpful
suggestions for maintaining flexibility in
applying the removal process and
suggested alternative plans for optimal
use of samples. For those chemicals
requiring large amounts of sample
volume to detect the chemicals,
alternatives such as less frequent
sampling or pooled analyses are
appropriate alternatives. CDC has
actively researched these alternatives
and will continue to weigh the relative
cost-benefit of other approaches in
addressing the issue of limited sample
volume. Such approaches could include
less frequent sampling, pooling of
samples, and development of more
sensitive analytical methods. For
difficult decisions, the NCEH/ATSDR
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 73, Number 61 (Friday, March 28, 2008)]
[Notices]
[Pages 16684-16685]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-6433]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the National Vaccine Program Office on Vaccine
Financing
AGENCY: Department of Health and Human Services, Office of the
Secretary.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (DHHS) is hereby
giving notice that the National Vaccine Program Office (NVPO) will
convene a meeting of the Vaccine Finance Working Group and is inviting
input from stakeholders on this issue. The meeting will be open to the
public.
DATES: The meeting will be held on Tuesday, April 29, 2008 and
Wednesday, April 30, 2008. The meeting will be held from 9 a.m. to 5
p.m. on both days.
ADDRESSES: Hilton Washington DC/Rockville Hotel and Executive Meeting
Center; 1750 Rockville Pike, Rockville, MD 20852-1699.
FOR FURTHER INFORMATION CONTACT: Angela Shen, National Vaccine Program
Office, Department of Health and Human Services, Room 443-H, Hubert H.
Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201;
(202) 260-1587, or e-mail angela.shen@hhs.gov.
SUPPLEMENTARY INFORMATION: NVPO has responsibility for coordinating and
ensuring collaboration among the many Federal agencies involved in
vaccine and immunization activities. The NVPO provides leadership and
coordination among Federal agencies, as they work together to carry out
the goals of the National Vaccine Plan. The National Vaccine Plan
provides a framework, including goals, objectives, and strategies, for
pursuing the prevention of infectious diseases through immunizations.
NVPO periodically convenes working groups to address specific issues
and topics that impact vaccine and immunization.
The Vaccine Finance Working Group was established to address issues
related to vaccine financing in the United States. The Working Group
has developed a draft white paper with a number of policy options to be
considered for presentation to the National Vaccine Advisory Committee
(NVAC) for discussion. NVPO has charged the Vaccine Finance Working
Group to obtain input from stakeholders whose viewpoints and interests
can help shape an understanding of the issues that are relevant to the
challenges in creating optimal approaches to vaccine financing in both
the public and private sectors.
The two-day meeting is scheduled to be held to provide an
opportunity for vaccine financing stakeholders to discuss and make
comments on the draft white paper and to solicit input, in particular,
regarding the conclusions and options made by the working group that
are contained in the draft document. A wide range of stakeholders
representing health care providers, employers, payers, health insurers,
vaccine manufacturers and distributors, consumers, and other interested
parties within the public health community are invited to attend the
meeting. Members of the public will have the opportunity to provide
comments at the meeting. Public comment will be limited to five minutes
per speaker. Any members of the public who wish to have printed
material distributed to meeting
[[Page 16685]]
participants should submit materials to the NVPO staff person
designated as the contact for additional information. All materials
should be submitted to the designated point of contact no later than
close of business April 21, 2008. Pre-registration is required for
public comment. Any individual who wishes to participate in the public
comment session should e-mail angela.shen@hhs.gov or call 202-690-5566.
There is limited space available for the public to attend this
meeting. However, it is desired that the public participate in the
discussions, as well. Registration is required to attend the meeting;
registration information can be found at: https://nvpo.constellagroup.com. Registration for the meeting will be accepted
until April 5, 2008. Registration after that date will be on the basis
of space availability. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the designated contact person.
Dated: March 24, 2008.
Bruce Gellin,
Director, National Vaccine Program Office.
[FR Doc. E8-6433 Filed 3-27-08; 8:45 am]
BILLING CODE 4150-44-P
